Drug name - Xeljanz Xr
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(5 months from now) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(3 years from now) | |
| CN1195755C | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1409712A | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1596257A | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| CN1325498C | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN200200588P1 | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN241773B | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN200401095P1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN251800B | PFIZER | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN218212B | PFIZER | Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN200607324P1 | PFIZER | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| EP1235830B1 | PFIZER | Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830A2 | PFIZER | Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339B1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339A1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1451192A1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| EP1451192B1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 11MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 22MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.